Wigmore Soloists review — rustic rollicking with The Soldier's Tale
It's 1918 and things aren't looking good for Stravinsky. He's holed up in Switzerland, having fled revolutionary Russia. His wife is sick, war is raging, work is scarce. He has to face that perennial (and increasingly pressing) question: what to do in turbulent times with limited resources. His answer was The Soldier's Tale, a work 'to be read, played and danced' about a soldier who gets tricked by the devil into swapping his violin — a symbol for the good, simple life — for the promise of 'untold riches'.
Like the soldier (and Stravinsky at the time), the work is of modest means. Small musical ideas, small movements, small ensemble — a chamber septet. The idea was that this troupe could tour Europe easily
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Record
7 minutes ago
- Daily Record
Love Island shock twist as girl brutally dumped from villa
First look into the action on tonight's episode of Love Island - as one Islander can't handle the pressure and another is sent packing... After an explosive launch episode, which saw over 1.4 million viewers tune into this year's Love Island, it's fair to say that summer has finally arrived. Last night Maya Jama announced the shocking news that one Islander will be sent home, cutting their time in the villa short, just 24 hours after they arrived. American bombshell Toni arrived and rocked the villa, leaving Shakira vulnerable and the other girls feeling the pressure to keep hold of their men. As we anticipate the outcome here is your sneak peek into tonight's episode of Love Island. The episode opens with Dejon checking in on Shakira to make sure she's okay with being left single - which leaves Meg feeling worried as she tells the other girls: "I don't have my man, Dejon's gone - that's it!" Meanwhile Shakira shows Dejon her vulnerable side, expressing: "That was a lot, it was intense, I was trying not to shake like a leaf. I've got a busy day ahead of me by the looks of it!" Later, Dejon and Meg head to the Terrace, with Dejon keen to reassure Meg. He tells her: "You haven't got anything to worry about, you're my favourite, one thing about me is I'll always be honest with my feelings." The next morning Toni and Shakira have a heart to heart, with Toni stating: "Just so you know, it wasn't personal, I'm rooting for else are you interested in?" To which Shakira replies: "Everyone!" and Toni says: "I'm telling you, I believe in you, you're not leaving." Shakira adds: "I know the boys are attracted to me on a surface level, but it's about whether we click." The singleton wastes no time getting her flirt on, as she asks Harry to join her on the terrace for a chat and things quickly heat up. The pair flirt back and forth as Shakira teases: "Haza you little minx!" as Harry jokingly replies, "It's day two come on let's keep it PG." Shakira doesn't stop at just Harry, as she pulls Conor, Blu and Tommy all for separate chats one after the other in hopes to find a connection. She confides in Tommy telling him: "I think it's best I try to get to know everyone." Shakira's chat with Tommy does not go down well with Megan as she takes matters into her own hands. With a push from Helena telling Megan to "claim your man!" She interrupts the conversation, sealing Tommy away for a chat. On the terrace, Megan confesses: "That made me a little bit jealous." But will Megan's jealous seeing Tommy with Shakira get the better of her, and push Tommy away? Later in the episode, as the Islanders get ready - with one getting ready for the final time in the villa - there is a tense feeling in the air as they know one of the girls will be going home tonight. Will Shakira's efforts be enough, or will she be sent packing? Maya makes a dramatic return to the Villa, telling the Islanders: "Your 24 hours are up, please meet me by the fire pit." At the fire pit Maya continues: "I gave you 24 hours to find a connection with one of the other boys or risk being dumped from the Island tonight, but have you done enough?" "Boys, do you wanna play it safe and stick with your current partner or take the risk and recouple with Shakira?" She then announces "Ok guys, if you feel you have a stronger connection with Shakira than your current couple, then please stand up…" As the girls watch on nervously, will any of the boys go for it and stand up for Shakira…or will it be Shakira herself packing up her suitcase?
Newsweek
7 minutes ago
- Newsweek
Elon Musk's Foreign Visitors Were Tracked By US: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. U.S. government agencies monitored visits by foreign nationals to properties owned by Elon Musk over concerns about potential efforts to influence the tech billionaire, The Wall Street Journal reported Tuesday, citing sources familiar with the matter. The investigation, which took place in 2022 and 2023, involved the Department of Homeland Security and the Justice Department, according to the report. It focused on individuals from Eastern Europe and other regions who had visited Musk. This is a breaking news story. Updates to follow.
